Our data demonstrate that PIK-93 treatment reduces the PD-L1 expression level on M1 macrophages along with tumor cells, suggesting that PIK-93 may potentially exert additive effects on more than one kind of PD-L1–positive cell in the TME, thus producing strong antitumor immunity. Here, CD274 is linked to neoplasm.